Pinkerton, Anthony B.; Sessions, E. Hampton; Hershberger, Paul; Maloney, Patrick R.; Peddibhotla, Satyamaheshwar; Hopf, Meghan; Sergienko, Eduard; Ma, Chen-Ting; Smith, Layton H.; Jackson, Michael R.; Tanaka, Jun; Tsuji, Takashi; Akiu, Mayuko; Cohen, Steven E.; Nakamura, Tsuyoshi; Gardell, Stephen J. published the artcile< Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators>, Reference of 3731-53-1, the main research area is urea nicotinamide phosphoribosyltransferase activator; NAD(+) booster; NAMPT; NAMPT activators; Ureas.
NAD+ is a crucial cellular factor that plays multifaceted roles in wide ranging biol. processes. Low levels of NAD+ have been linked to numerous diseases including metabolic disorders, cardiovascular disease, neurodegeneration, and muscle wasting disorders. A novel strategy to boost NAD+ is to activate nicotinamide phosphoribosyltransferase (NAMPT), the putative rate-limiting step in the NAD+ salvage pathway. We previously showed that NAMPT activators increase NAD+ levels in vitro and in vivo. Herein we describe the optimization of our NAMPT activator prototype (SBI-0797812) leading to the identification of 1-(4-((4-chlorophenyl)sulfonyl)phenyl)-3-(oxazol-5-ylmethyl)urea (34) that showed far more potent NAMPT activation and improved oral bioavailability.
Bioorganic & Medicinal Chemistry Letters published new progress about Cardiovascular disease. 3731-53-1 belongs to class pyridine-derivatives, and the molecular formula is C6H8N2, Reference of 3731-53-1.